{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diabetic+Chronic+Kidney+Disease&page=2",
    "query": {
      "condition": "Diabetic Chronic Kidney Disease",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diabetic+Chronic+Kidney+Disease&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T00:23:52.950Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02065791",
      "title": "Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 4401,
      "start_date": "2014-02-17",
      "completion_date": "2018-10-30",
      "has_results": true,
      "last_update_posted_date": "2019-12-05",
      "last_synced_at": "2026-07-24T00:23:52.950Z",
      "location_count": 152,
      "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 149 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02065791"
    },
    {
      "nct_id": "NCT02251431",
      "title": "Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Chronic Kidney Disease",
        "Left Ventricular Diastolic Dysfunction"
      ],
      "interventions": [
        {
          "name": "BYDUREON",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2015-11",
      "completion_date": "2019-12",
      "has_results": true,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-07-24T00:23:52.950Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02251431"
    },
    {
      "nct_id": "NCT07271186",
      "title": "Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Kidney Disease (DKD)"
      ],
      "interventions": [
        {
          "name": "ALN-ANG3",
          "type": "DRUG"
        },
        {
          "name": "Evinacumab",
          "type": "DRUG"
        },
        {
          "name": "ALN-ANG3 placebo",
          "type": "DRUG"
        },
        {
          "name": "Evinacumab placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 270,
      "start_date": "2026-01-09",
      "completion_date": "2028-04-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-07-24T00:23:52.950Z",
      "location_count": 57,
      "location_summary": "Huntsville, Alabama • Little Rock, Arkansas • Huntington Beach, California + 46 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07271186"
    },
    {
      "nct_id": "NCT00120328",
      "title": "To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "SPP301",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Speedel Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 2364,
      "start_date": "2005-07",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2007-10-05",
      "last_synced_at": "2026-07-24T00:23:52.950Z",
      "location_count": 1,
      "location_summary": "Greenville, North Carolina",
      "locations": [
        {
          "city": "Greenville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00120328"
    },
    {
      "nct_id": "NCT02823600",
      "title": "Feasibility Study of Retinal Screening Using the RetinaVue 100 Camera in Outpatient Dialysis Centers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Failure, Chronic",
        "Eye Diseases",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "RetinaVue 100 camera",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2016-07",
      "completion_date": "2017-05",
      "has_results": true,
      "last_update_posted_date": "2018-07-20",
      "last_synced_at": "2026-07-24T00:23:52.950Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02823600"
    },
    {
      "nct_id": "NCT00421733",
      "title": "The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Nephropathy",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Zemplar (paricalcitol) capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 281,
      "start_date": "2006-12",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2012-01-20",
      "last_synced_at": "2026-07-24T00:23:52.950Z",
      "location_count": 27,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • Yuba City, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Yuba City",
          "state": "California"
        },
        {
          "city": "Hudson",
          "state": "Florida"
        },
        {
          "city": "Lauderdale Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00421733"
    },
    {
      "nct_id": "NCT07444203",
      "title": "Transformative Research in Diabetic Nephropathy 2.0",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Nephropathies",
        "Kidney Diseases",
        "Renal Insufficiency, Chronic",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Sodium-glucose cotransporter 2 inhibitors (SGLT2i)",
          "type": "DRUG"
        },
        {
          "name": "Renin-angiotensin-aldosterone system blockade",
          "type": "DRUG"
        },
        {
          "name": "Glucagon-like peptide-1 receptor agonists (GLP 1 RA)",
          "type": "DRUG"
        },
        {
          "name": "Mineralocorticoid Receptor Antagonists(MRAs)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-11-12",
      "completion_date": "2028-11-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-07-24T00:23:52.950Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07444203"
    },
    {
      "nct_id": "NCT05047263",
      "title": "A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-diabetic Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Finerenone (BAY94-8862)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1584,
      "start_date": "2021-09-21",
      "completion_date": "2026-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-07-24T00:23:52.950Z",
      "location_count": 57,
      "location_summary": "Huntsville, Alabama • Chula Vista, California • El Centro, California + 49 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05047263"
    },
    {
      "nct_id": "NCT02276742",
      "title": "Lifestyle Management of CKD in Obese Diabetic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Type 2 Diabetes",
        "Chronic Kidney Disease (CKD)"
      ],
      "interventions": [
        {
          "name": "Social Cognitive Theory",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Monitoring",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 269,
      "start_date": "2014-10",
      "completion_date": "2019-11-08",
      "has_results": false,
      "last_update_posted_date": "2020-07-14",
      "last_synced_at": "2026-07-24T00:23:52.950Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02276742"
    },
    {
      "nct_id": "NCT05182840",
      "title": "A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Disease, Chronic"
      ],
      "interventions": [
        {
          "name": "BI 690517",
          "type": "DRUG"
        },
        {
          "name": "Placebo to BI 690517",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo to empagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 714,
      "start_date": "2022-01-11",
      "completion_date": "2023-07-10",
      "has_results": true,
      "last_update_posted_date": "2024-10-22",
      "last_synced_at": "2026-07-24T00:23:52.950Z",
      "location_count": 41,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Canyon Country, California + 34 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Canyon Country",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05182840"
    }
  ]
}